Welcome to our dedicated page for Oncotelic Therapeutics news (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on Oncotelic Therapeutics stock.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) generates a diverse stream of news centered on oncology, rare pediatric cancers, RNA-based therapeutics, AI-driven discovery, and nanomedicine. As a clinical-stage biopharmaceutical company, it regularly reports on scientific publications, joint venture progress, platform launches, and financing developments that shape its pipeline and corporate strategy.
Investors and researchers following OTLC news will encounter updates on key assets such as OT-101, a TGFB2 antisense agent associated with rare pediatric designation for DIPG through joint venture GMP Bio, and Sapu003, an intravenous Deciparticle formulation of everolimus developed by 45% owned JV Sapu Nano. Press releases highlight biomarker frameworks for identifying tumors likely to respond to Sapu003, pharmacokinetic data showing reduced gastrointestinal accumulation compared with oral everolimus, and broader Deciparticle platform data demonstrating formulation of multiple hydrophobic drug classes.
Oncotelic’s news flow also covers its PDAOAI evidence-interrogation platform, including open access for researchers to a TGF-β knowledge corpus of more than 125,000 PubMed abstracts via a dedicated Discord channel. Additional announcements describe peer-reviewed publications on context-dependent biomarkers in liver and pancreatic cancer, sub-15 nm nanoparticles for drug delivery, and survival-associated biological axes such as TGFB2, DNMT3A, and GMPS.
From a corporate and capital markets perspective, OTLC news includes independent valuations of its joint venture GMP Bio pipeline, potential fair-value remeasurements under U.S. GAAP, and registration statements related to equity purchase and note agreements with institutional investors. Regularly reviewing this news page allows readers to track how scientific advances, joint venture activities, AI platforms, and financing structures intersect within Oncotelic’s evolving oncology and rare disease portfolio.
Oncotelic Therapeutics (OTCQB:OTLC) announced participation in Biotechgate Digital Partnering from Aug 29 - Sep 2, 2022. The company focuses on developing treatments for rare conditions like Parkinson's disease and certain cancers, particularly pediatric cancers. Oncotelic has joint ventures and its own product candidates, including AL-101 for Parkinson's and erectile dysfunction. As of now, over 1 million patients in the US have Parkinson's, with numbers projected to rise. The company has completed several clinical trials for its therapies, including OT-101 for cancer and COVID-19.
Oncotelic Therapeutics (OTCQB:OTLC) announced the availability of its presentation at the 7th JCA-AACR Special Joint Conference, focusing on its clinical findings for OT-101 treatment in pancreatic cancer. Key results indicate that over 55% of treated patients achieved long-term disease control, significantly improving median overall survival to 9.3 months compared to 2.6 months (p0.0001). Additionally, high AUC levels during subsequent chemotherapy correlated with a median overall survival of 9.6 months (p=0.0006). The presentation can be accessed through their website and YouTube.
Oncotelic Therapeutics, Inc. (OTCQB:OTLC) announced its presentation at the BIO International Convention is now available. The company is on track for a Joint Venture Company initial public offering in 2023, with a minimum valuation of $200M and a potential range of $1B to $5B. They are combining their drug OT-101 with established immunotherapies, with promising results reported in COVID-19 mortality rates. OT-10 has shown a significant reduction in mortality among high-risk COVID patients, with a statistical significance of p=0.003.
Oncotelic Therapeutics (OTCQB:OTLC) announced the FDA clearance for its Phase 2 clinical trial protocol targeting metastatic pleural mesothelioma (MPM). This trial, in collaboration with Merck, utilizes pembrolizumab and aims to investigate the combination of TGF-β inhibition (OT-101) with anti-PD-1 therapy. The study will enroll up to 63 patients and assess tumor response, safety, and tolerability, with primary objectives focusing on improving overall response rates in MPM patients who haven't responded to existing treatments.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) reported Q1 2022 financial results, showing a net loss of $5 million, compared to a loss of $3.1 million in Q1 2021. R&D expenses decreased to $580K from $1.6 million due to reduced clinical trial activity. G&A expenses increased by $3.3 million, largely due to non-cash stock compensation. The company established a joint venture with Dragon Overseas and GMP Bio, which could yield up to $50 million upon OT-101's marketing approval. Oncotelic aims to uplift to a national exchange, supported by this JV which transfers clinical trial costs away from the company.
Oncotelic Therapeutics (OTCQB:OTLC) announced its participation in the BIO International Convention in San Diego from June 13-16, 2022. CEO Dr. Vuong Trieu will present an overview of the company's pipeline, highlighting Sapu Therapeutics, a subsidiary in collaboration with Dragon Overseas Capital Ltd. and GMP Biotechnology. Oncotelic focuses on developing treatments for rare diseases, particularly in oncology and neurodegenerative conditions like Parkinson's Disease, with a market of over 1 million patients in the U.S. alone.
Oncotelic Therapeutics (OTCQB:OTLC) announced the grant of patent application no. 15/753,882 by the US Patent Office, focusing on a pharmaceutical composition to enhance anti-tumor effects using Vascular Disrupting Agents (VDAs) like combretastatin A4 phosphate. The CEO, Dr. Vuong Trieu, highlighted strengthening legacy assets including CA4P and Oxi4503 for challenging cancers, in conjunction with Pembrolizumab. The company is also targeting Parkinson's and erectile dysfunction with its acquired product AL-101, aiming for significant market needs amidst increasing patient diagnoses.
Oncotelic Therapeutics (OTLC) has appointed Dr. Seymour Fein as Chief Regulatory Officer, tasked with guiding the company’s registration trials globally. His extensive experience includes overseeing FDA approvals for over 20 drugs and managing the clinical consulting firm CNF Pharma. Following the completion of a joint venture for OT-101, a TGF-β antisense drug with demonstrated efficacy against hard-to-treat cancers, Dr. Fein aims to enhance Oncotelic's drug development efforts. The company focuses on improving treatment outcomes, especially in rare pediatric cancers.
Oncotelic Therapeutics (OTLC) has appointed Dr. Fatih Uckun as Chief Medical Officer, enhancing its leadership at a pivotal time for the company. Dr. Uckun, a veteran in oncology with over 30 years of experience, will oversee the execution of crucial registrational trials for OT-101, aimed at treating difficult cancers such as DIPG and pancreatic cancer. His extensive background includes significant achievements in immunotherapy research. The company recently completed a joint venture for OT-101, which has shown promise in previous clinical trials, including positive outcomes in treating COVID-19.
Oncotelic Therapeutics, Inc. (OTCQB:OTLC) announced its financial results for FY 2021, revealing a net loss of approximately $10.5 million, compared to a $10 million loss in FY 2020. The company reported no service revenue in FY 2021, a decline from $1.7 million in FY 2020. Research and development expenses decreased to $3.7 million, while general and administrative costs increased to $5.5 million. The company formed a joint venture with Dragon Overseas, expected to reduce future expenses, and anticipates significant operational changes in FY 2022, focusing on new drug developments and potential uplisting to a national stock exchange.